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Vascular dysfunction is an early feature of diabetic vascular disease, due to increased oxidative stress and reduced nitric oxide (NO)
bioavailability. This can lead to endothelial cell senescence and clinical complications such as stroke. Cells can become senescent
by shortened telomeres and oxidative stress is known to accelerate telomere attrition. Sirtuin 1 (SIRT1) has been linked to vascular
health by upregulating endothelial nitric oxide synthase (eNOS), suppressing oxidative stress, and attenuating telomere shortening.
Accelerated leukocyte telomere attrition appears to be a feature of clinical type 2 diabetes (T2D) and therefore the telomere system
may be a potential therapeutic target in preventing vascular complications of T2D. However the effect of T2D on vascular telomere
length is currently unknown.We hypothesized that T2D gives rise to shortened leukocyte and vascular telomeres alongside reduced
vascular SIRT1 expression and increased oxidative stress. Accelerated telomere attrition was observed in circulating leukocytes, but
not arteries, in T2D compared to control rats. T2D rats had blunted arterial SIRT1 and eNOS protein expression levels which were
associated with reduced antioxidant defense capacity. Our findings suggest that hyperglycemia and a deficit in vascular SIRT1 per
se are not sufficient to prematurely shorten vascular telomeres.
1. Introduction
Type 2 diabetes (T2D) is one of the leading causes ofmortality
worldwide, largely due to vascular complications including
myocardial infarction and stroke [1, 2]. Endothelial function,
a key determinant of vascular health, is impaired in the
diabetic vasculature primarily due to reduced nitric oxide
(NO) bioavailability that is brought about by a combination
of uncoupling and inhibition of endothelial nitric oxide
synthase (eNOS) and an excessive production of reactive
oxygen species (ROS) [3]. Loss of NO bioactivity, leading
to endothelial dysfunction, is known to predispose patients
to developing secondary complications such as stroke [4].
Therefore understanding the mechanisms associated with
vascular dysfunction is critical to the development of ther-
apeutic targets in the hope of preventing T2D-related mor-
bidity.
The NAD+-dependent deacetylase, sirtuin 1 (SIRT1), is
abundantly expressed in the vasculature [5] and deacetylates
a number of substrates that are key modulators of vascular
function including eNOS [6] and FOXO1 [7]. SIRT1 has
been reported to be downregulated in peripheral blood
mononuclear cells of obese humans [8] and in the liver and
pancreas of rodents on a high-fat diet [9]. The effect of
T2D on microvascular SIRT1 expression is less clear. High-
fat feeding resulted in a significant decrease in mouse aorta
SIRT1 protein expression [10], while no changes were seen in
the cerebral vasculature in obese Zucker rats [11].
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SIRT1 interacts with specific double-stranded repeat
sequences of DNA at the extremities of chromosomes [5󸀠-
(TTAGGG)n-3
󸀠], known as telomeres [12]. During each
round of cell division, telomeres shorten until they reach a
critical length [13]. At this point, the cell can no longer repli-
cate and it becomes either senescent or apoptotic, thereby
creating an accelerated aging phenotype and increasing
risk of secondary disease [14]. Telomere shortening can be
prematurely accelerated in vitro in the face of oxidative stress
[15], a hallmark of T2D [16]. Therefore restoring telomere
health may be an important therapeutic target in preventing
vascular complications of T2D. Although epidemiological
studies have suggested an association between T2D and
shortened leukocyte telomeres [17, 18], a direct cause and
effect relationship has never been established. Moreover it
is not known whether vascular telomeres have accelerated
shortening in T2D.
2. Materials and Methods
2.1. Animal Model of Type 2 Diabetes. All animal procedures
were carried out in accordance with the Australian Code
for the Responsible Conduct of Research and were approved
by the Flinders University Animal Ethics Committee. Male
hooded Wistar rats (𝑛 = 17) were bred and housed under
controlled room temperature with a 12 : 12 hour light-dark
cycle in the School of Medicine Animal Care Facility at
Flinders University.
After weaning at three weeks of age, rats were randomly
assigned into two groups: diabetic and control. The diabetic
group (𝑛 = 9; T2D) was placed on a high-fat diet which con-
sisted of 45 kcal% fat, 35 kcal% carbohydrate, and 20 kcal%
protein (D12451; Open Source Diet). The chow was custom-
made by Gordon’s specialty stockfeed (Yanderra, Australia).
The remaining group (𝑛 = 8; control) was maintained on
a control diet which contained 10 kcal% fat, 70 kcal% car-
bohydrate, and 20 kcal% protein (D12450H; Open Source
Diet). Animals had free access to water and their assigned
diets. After 18 weeks on the diet regimen, the diabetic
groupwas given an intraperitoneal injection of streptozotocin
(30mg/kg body weight) dissolved in saline while the control
group was injected with the same volume of vehicle. Both
groups were maintained on their respective diets for an
additional eight weeks. A timeline is shown in Figure 1.
Previous studies have shown that a high-fat feeding followed
by a low dose of streptozotocin induces a mild impairment of
insulin secretion, similar to that seen in late stage T2D [19].
2.2. Measurement of Blood Pressure. Five days prior to sac-
rifice, rats were anesthetized with 3% isoflurane and their
body temperature was maintained on a heating pad at 37∘C.
Blood pressure was measured using MLT125/R pulse trans-
ducer/pressure cuff and IN125 NIBP controller (AD Instru-
ments, Australia) and recorded using PowerLab software (AD
Instruments, Australia). Systolic pressure was determined
from the average of three consecutive readings obtained from
each rat.
2.3. Sample Collection. On the day of sacrifice, animals were
weighed and anesthetized with isoflurane. Blood glucose was
measured from the tail vein using an Accu-Chek Performa
glucometer and test strips (Roche Diagnostics, Indianapolis,
IN, USA). The animals were then decapitated using a rodent
guillotine and trunk blood obtained for measurement of
serum insulin and free fatty acids, plasma triglycerides, and
C-reactive protein (CRP) and for extraction of DNA using
a DNeasy blood and tissue kit (Qiagen) according to the
manufacturer’s instructions. The DNA concentration of each
extractionwasmeasured in triplicate using aNanoDrop 2000
(Thermo Scientific).
The left and right femoral artery were excised from
animals, cleaned of connective tissue, and washed to remove
blood. The size of each artery was 0.9 cm in length, 2mm
in en face width, and approximately 1mg in weight. Arteries
were immediately snap frozen in liquid nitrogen and stored
at −80∘C. DNA was extracted using a QIAamp DNA micro
kit (Qiagen) according to themanufacturer’s instructions and
stored at −80∘C until analysis.
The brain was removed and the middle cerebral arteries
were carefully harvested and pooled into 180 𝜇L modified
radioimmunoprecipitation (RIPA) buffer containing 50mM
Tris, pH 7.8 with 150mM NaCl, 1% Triton X-100, 0.5%
Nonidet P-40, 0.25% sodium deoxycholate, and 1mM PMSF
and protease inhibitor cocktail (Roche, Indianapolis, IN,
USA). Total protein was extracted as previously described
[20] and stored at −80∘C.
2.4. Immunoblotting. Total protein was measured using EZQ
Protein Quantitation (Roche Diagnostics, Indianapolis, IN,
USA). Cerebral artery lysate was then combined with
Laemmli sample buffer and heated to 95∘C for 5mins. Equal
amounts of protein (18 micrograms) were loaded onto each
lane of a stain-free gel (Bio-Rad Laboratories, Hercules, CA,
USA) alongside Dual Color Precision Plus protein standard
(Bio-Rad Laboratories). Total protein loaded on the gel
and then transferred to the low fluorescence polyvinylidene
difluoride (PVDF) membrane was imaged (ChemiDoc MP
imager, Bio-Rad Laboratories) and analysed using Image Lab
4.0.1 software (Bio-Rad Laboratories). Previous studies have
shown that this method of protein normalization is superior
to that of either total protein stains (e.g., Sypro Ruby, Amido
Black, andCoomassie Blue) or antibody loading controls [21].
Membranes were probed with an antibody directed
against either SIRT1 (Abcam), eNOS (BD Transduction
Labs), Nox2 (BD Transduction Laboratories), manganese
superoxide dismutase (MnSOD; Millipore), p66Shc (Milli-
pore), or 3-nitrotyrosine (Abcam) overnight at 4∘C. The
next day, membranes were washed and incubated with the
appropriate secondary antibody (Jackson ImmunoResearch).
Bands were visualized using enhanced chemiluminescence,
captured with a digital acquisition system (Fujifilm, Japan)
and quantified (Carestream Molecular Imaging software,
Rochester, NT, USA). Densitometry results are expressed
relative to total protein and normalized to the control group.
2.5. Singleplex Telomere qPCR Assay. Mean telomere length
was measured using a singleplex assay similar to that
described by Cawthon [22]. The telomere and single-copy
gene (𝛽-actin) were amplified in separate singleplex reactions
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Figure 1: Timeline depicting the initiation of the assigned diet (high-fat or control diet), administration of streptozotocin or vehicle, blood
pressure measurement, and tissue harvesting followed by termination.
because the efficiency of each amplicon was optimal in dif-
ferent mastermixes (assessed in pilot studies). The telomere
primers were used as previously described by Cawthon [23]
and used at a concentration of 900 nM.The single-copy gene
(𝛽-actin) primer sequences (written 5󸀠 → 3󸀠) were 𝛽-actin-
F, AGG TCA TCA CTA TCG GCA ATG A, and 𝛽-actin-R,
GAG ACT ACA ACT TAC CCAGGA AGGAA, and used at
a final concentration of 2 𝜇M.
Each qPCR reaction was conducted in a total volume
of 20𝜇L using 384-well plates and performed on a ViiA 7
real-time PCR instrument (Life Technologies, Foster City,
CA). The telomere assay was amplified in a custom-made
mastermix as described by Cawthon [23] and the 𝛽-actin
assay was amplified in Power SYBR green PCR mastermix
(Life Technologies).
For the telomere assay, a standard curve was run along-
side the experimental samples consisting of a calibrator DNA
sample which was diluted serially by 5-fold to produce five
concentrations of DNA ranging from 515 to 0.824 ng/mL. For
the 𝛽-actin assay, a standard curve was run alongside the
experimental samples consisting of the same calibrator DNA
sample which was diluted serially by 5-fold to produce five
concentrations of DNA ranging from 5150 to 8.24 ng/mL.The
calibrator was rat DNA extracted from either whole blood or
femoral artery.
2.6. TelomereData Analysis. Theamount of telomerewas cal-
culated as 𝑇 = 𝐸(Cqcalibrator−Cqsample), where 𝐸 was the efficiency
of the telomere primer calculated from the standard curve,
Cqcalibrator was the Cq of the 1 : 5 dilution on the standard
curve, and Cqsample was the Cq of the experimental sample.
The amount of 𝛽-actin (reference gene) was calculated as 𝑆 =
𝐸
(Cqcalibrator−Cqsample), where 𝐸 was the efficiency of the 𝛽-actin
primer calculated from the standard curve, Cqcalibrator was the
Cq of the 1 : 5 dilution on the standard curve, and Cqsample
was the Cq of the experimental sample. Relative telomere
length (𝑇/𝑆) was estimated as the ratio between the amount
of telomere (𝑇) and reference gene (𝑆).
2.7. Drugs and Reagents. Streptozotocin was purchased from
Sigma. Fresh streptozotocin stock solutions of 50mg/mL
were made in saline. The 𝛽-actin and telomere primers were
synthesized by GeneWorks (Thebarton, SA, Australia) and
dissolved in water for injection (GlaxoSmithKline).
2.8. Statistical Analysis and Power. All data are expressed as
mean ± standard error of the mean. Statistical comparisons
were performed using GraphPad InStat version 3 software
(GraphPad software, La Jolla, CA, USA) using an unpaired
𝑡-test. Statistical significance was accepted at 𝑃 < 0.05.
The initial power analysis was performed based on previous
telomere length studies in rodents [24, 25]. The experiment
was powered at 80% to detect a 20% change in telomere
length, assuming a two-tailed alpha level of 5%.
3. Results
3.1. Phenotypic Assessment of Animals Fed a High-Fat Diet fol-
lowed by a LowDose of Streptozotocin. Rats fed a high-fat diet
for 18 weeks weighed significantly more than age-matched
control rats fed a control diet (𝑃 = 0.029; see Table 1).
Animals then received either a low dose of streptozotocin
or vehicle and the diet regimen was continued for another
eightweeks.One rat died just prior to streptozotocin injection
and two rats died the following week after streptozotocin
injection. Systolic blood pressure was similar in both T2D
rats and control rats (𝑃 = 0.16; 113 ± 8mmHg versus 105 ±
5mmHg, resp.). On the day of sacrifice, T2D rats weighed
significantly less than the control group (𝑃 = 0.0001; 358 ±
12 g versus 432 ± 7 g, resp.).
Fasting plasma glucose levels were significantly higher
in T2D rats compared to control rats (𝑃 < 0.0001; 24.2
± 1.3mM versus 8.6 ± 0.3mM, resp.). Circulating free fatty
acid concentration was significantly elevated in T2D rats
compared to control rats (𝑃 = 0.012; 0.51 ± 0.06mM
versus 0.34 ± 0.02mM, resp.). Plasma insulin concentration
was significantly lower in T2D rats compared to the control
rats (𝑃 = 0.0028; 0.5 ± 0.1 ng/mL versus 2.8 ± 0.5 ng/mL,
resp.), a reflection of streptozotocin-induced pancreatic 𝛽-
cell dysfunction. As a marker of systemic inflammation,
plasma CRP was significantly elevated in T2D compared to
control rats (𝑃 < 0.0001; see Table 1).
3.2. Mean Telomere Length in Femoral Artery and Whole
Blood. As shown in Figure 2(a), arterial telomere length was
comparable betweenT2D rats and control rats (𝑃 = 0.28; 0.92
± 0.04 versus 0.81 ± 0.08, resp.). However leukocyte telomere
length was significantly shorter in T2D compared to the
control group (𝑃 = 0.034; 0.49± 0.14 versus 1.09± 0.19, resp.).
Thepercent efficiency of𝛽-actin and telomere primers ranged
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Table 1: Phenotype of control (𝑛 = 8) and T2D (𝑛 = 6) rats. Values
are presented as mean ± standard error of the mean. ∗ indicates 𝑃 <
0.05 between T2D and control.
Control T2D 𝑃 value
Weight at injection (g) 387 ± 5 413 ± 9 0.029∗
Final weight (g) 432 ± 7 358 ± 12 0.0001∗
Systolic pressure (mmHg) 105 ± 5 113 ± 5 0.15
Glucose (mM) 8.6 ± 0.3 24.2 ± 1.3 <0.0001∗
Insulin (ng/mL) 2.8 ± 0.5 0.5 ± 0.1 0.0028∗
Triglycerides (mM) 1.4 ± 0.1 2.0 ± 0.4 0.14
Free fatty acids (mM) 0.34 ± 0.02 0.51 ± 0.06 0.012∗
CRP (ng/mL) 16 ± 0.7 263 ± 23 <0.0001∗
between 92 and 102%. The PCR amplification products were
visualized by agarose gel electrophoresis, ethidium bromide
staining, and UV transillumination (see Figure 2(b)). The
𝛽-actin PCR product was observed at the expected size of
81 base pairs while the telomere PCR product showed a
main product at 82 base pairs (the sum of the length of
the two telomere primers) and a smear to 150 base pairs,
reflecting longer PCR products due to staggered annealing
of the primers. This is consistent with other reports in the
literature [22, 26].
3.3. Vascular Protein Expression. Vascular SIRT1 and eNOS
protein expression were significantly lower in T2D rats
compared to their control counterparts (𝑃 = 0.0082 and 𝑃 =
0.011, resp.; see Figure 3). MnSOD and p66Shc protein levels
were significantly lower in T2D rats compared to control
rats (𝑃 = 0.039 and 𝑃 = 0.028, resp.); however total 3-
nitrotyrosine-containing proteins andNox2were comparable
between groups (Figure 4).
4. Discussion
There are two major findings of the present study. Firstly,
we have demonstrated that T2D causes selective accelerated
telomere shortening in circulating leukocytes but preserved
telomere length in arteries. To our knowledge, this is the
first direct evidence of leukocyte telomere shortening in T2D.
Secondly, althoughhyperglycemia leads to blunted SIRT1 [27]
and telomere shortening [28], we have shown in vivo that
hyperglycemia and a deficit in vascular SIRT1 per se are not
sufficient to prematurely shorten vascular telomeres.
4.1. Phenotype of T2D Rats. Here we have shown that rats
gained significantly more weight after an 18-week high-
fat diet regimen (see Table 1). Injection of a low dose of
streptozotocin significantly increased blood glucose levels
in T2D rats, which is consistent with other reports [29].
Circulating insulin levels were significantly decreased, a
feature of clinical late stage T2D when the pancreatic beta
cells become impaired and insulin secretion is reduced [30].
The animals also showed evidence of dyslipidemia that is in
line with elevated plasma free fatty acids observed in human
T2D [31] that has been linked to the onset of insulin resistance























Figure 2: (a) Leukocyte 𝑇/𝑆 ratio was significantly lower in T2D
rats compared to control rats (𝑃 = 0.034; 𝑡-test). Femoral artery 𝑇/𝑆
ratio was comparable between T2D and control rats (𝑃 = 0.28). (b)
qPCR products for rat 𝛽-actin and telomere primers. Lane 1: DNA
ladder; lanes 2 and 6: rat leukocyte calibrator DNA; lanes 3 and 7:
control rat leukocyte DNA; lanes 4 and 8: T2D rat leukocyte DNA;
lanes 5 and 9: no template control (H
2
O).
levels of CRP, confirming that this animal model is a good
representation of T2D in humans which is associated with
prolonged low-grade inflammation [33].
4.2. Leukocyte Telomere Length Is Shorter in T2D. We
found that leukocyte telomere length is shorter in T2D rats
compared to control rats. Our findings are in line with
accumulating clinical studies showing a correlation between
T2D and shorter leukocyte telomeres [17, 18, 34, 35]. One
possible explanation for the shorter leukocyte telomeres in
T2D is that it reflects increased leukocyte turnover due to the
systemic low-grade inflammation. However clinical studies
have failed to show a significant inverse correlation between





















Figure 3: Arterial protein expression levels of SIRT1 and eNOSwere
decreased in T2D rats compared to control rats (𝑛 = 3 each; 𝑃 =
0.0082 and 𝑃 = 0.011, resp.; 𝑡-test). Representative immunoblots
are shown below the summary data. Relative protein levels were
calculated as the ratio of the intensity of the chemiluminescent
bands to the intensity of the total protein loaded on the gel and are
expressed as a percentage of the values measured in control rats.
leukocyte telomere length and markers of inflammation [35–
37]. Tentolouris and colleagues [38] have previously reported
a correlation between telomere length and nitrosative stress.
Taken together, we speculate that the observed leukocyte
telomere attrition may be due, at least in part, to nitrosative
stress which is absent within the vasculature in this animal
model of T2D (see below).
4.3. Vascular Telomere Length Is Comparable in T2D and
Controls. Shortened vascular telomere length has been pre-
viously documented in human coronary heart disease [39],
atherosclerosis [40], and abdominal aortic aneurysms [41].
Because vascular biopsies cannot be taken from obese or
T2D patients without overt vascular pathology, leukocyte
telomere measurements have been used as a surrogate for
predicting vascular disease risk [42]. We have shown for
the first time that arterial telomere length is preserved in
T2D rats compared to control rats. Although SIRT1 depletion
[43] and hyperglycemia [28] have previously been shown
to independently accelerate telomere shortening, our results
have shown that hyperglycemia and blunted vascular SIRT1
in vivo were not sufficient to prematurely shorten arterial
telomeres. Our experiments were sufficiently powered at 80%
to detect a 20% change in telomere length.Therefore a smaller
change in telomere length would not have been detected
and as a result we cannot rule out the possibility that there
are more subtle changes in telomere length within the T2D
vasculature. Nevertheless our data suggests that leukocyte
telomere length may not be an optimal surrogate for vascular






















Figure 4: Arterial protein expression levels of MnSOD and p66Shc,
but not Nox2 or 3-NT, were significantly decreased in T2D rats
compared to control rats (𝑛 = 3 each; 𝑃 = 0.039 and 𝑃 =
0.028, resp.; t-test). Representative immunoblots are shown below
the summary data. Relative protein levels were calculated as the ratio
of the intensity of the chemiluminescent bands to the intensity of the
total protein loaded on the gel and are expressed as a percentage of
the values measured in control rats.
4.4. Vascular SIRT1 and eNOS Protein Expression Are Reduced
in T2D. SIRT1 protein expressionwas significantly decreased
in resistance-sized vessels harvested fromT2D rats compared
to control rats on a normal diet (standard chow).Our findings
are in line with studies showing a decline in SIRT1 levels at
the level of the macrovasculature (aorta) after six months
of high-fat feeding [10]. However it is important to assess
protein expression within the resistance-sized vessels, since
these vessels are fundamental to the control of blood flow
[44]. We have now confirmed for the first time that SIRT1
protein expression is blunted within the microvasculature in
T2D.
The mechanisms leading to a decline in SIRT1 expression
in T2D are incompletely understood. SIRT1 activity has been
shown to be controlled by both nutritional status and the
cellular redox status (NAD+/NADH ratio). In a nutrient
rich environment, NAD+/NADH ratio is blunted due to an
increased rate of reduction of NAD+ to NADH, leading to a
decrease in SIRT1 activity [10]. Endothelial progenitor cells
[45], human umbilical vein endothelial cells [27], and mouse
brain endothelial cells (Sokoya et al., unpublished findings)
cultured in high glucose have lower levels of SIRT1 protein
expression. Recent studies have also shown that oxidative
stress directly inhibits SIRT1 activity via oxidative posttrans-
lational modifications [46]. Therefore, both a reduction in
6 Journal of Diabetes Research
cellular redox status and an increase in oxidant stress may be
working together to reduce vascular SIRT1 expression.
NO is an important signalling molecule in the vascular
system. The production of endothelial-derived NO is key
in mediating relaxation of the cerebral vasculature [47].
Our study has found that T2D leads to significantly lower
eNOS protein levels within cerebral arteries. This may be
mediated in part by CRP, which has been shown to directly
decrease eNOS protein expression and activity [48] and/or
hyperglycemia that promotes eNOS glycosylation thereby
reducing the active form of NO [49]. A reduction in total
eNOS production suggests that NO bioavailability may be
reduced, potentially leading to blunted endothelial-mediated
relaxations, which have previously been shown in this model
[50].
4.5. Vascular Antioxidant Protein Expression Is Reduced in
T2D. Our observation that vascularMnSOD protein expres-
sion is blunted in T2D suggests that the antioxidant pathway
is being overwhelmed, presumably due to an increase in
superoxide production within the vasculature.This is consis-
tent with other data showing downregulation of MnSOD in
the vasculature after high-fat feeding [51].
Vascular p66Shc protein expression was also signifi-
cantly lower in T2D rats compared to controls. As a redox
mitochondrial enzyme, p66Shc has been shown to generate
mitochondrial ROS (hydrogen peroxide) [52]. Howevermore
recent studies have localized p66Shc to the cytoplasm where
it is regulated by the redox sensitive transcription factor,
NFE2-related factor 2 (Nrf2) [53]. Nrf2 regulates the antioxi-
dant response element (ARE/EpRE) mediated expression of
antioxidant enzymes. In this way, cytosolic p66Shc serves
as an antioxidant protein. Our finding of blunted vascular
p66Shc protein levels in T2D is in accordance with a recent
report of reducedNrf2 signaling inmouse brain after high-fat
feeding [54].
Interestingly, SIRT1 itself has been shown to play an
important role in regulating antioxidant gene expression
in endothelial cells by enhancing the stability of the
FoxO3a/PGC-1𝛼 complex, which promotes antioxidant gene
expression [7]. In this way, blunted vascular SIRT1 in T2D
could mediate, at least in part, the observed decrease in
antioxidant protein expression.
4.6. Source of Vascular Superoxide. Vascular NADPH oxi-
dases are one of the major sources of ROS in the cardio-
vascular system [55]. In our study, we examined a subunit
of NADPH oxidase, Nox2, which has previously shown
to be significantly increased in mouse aorta after high-fat
feeding [56]. However, in our animal model of T2D, Nox2
levels were uncompromised in cerebral artery homogenates.
Nevertheless there are additional sources of superoxide
including cyclooxygenase [57], xanthine oxidase [58], and
other NADPH oxidases such as Nox1 and Nox5 [55].
4.7. Nitrosative Stress. Superoxide can react with NO to form
peroxynitrite which in turn promotes nitration of tyrosine
residues in proteins leading to nitrotyrosine-containing pro-
teins. In the present study, we found that the abundance of
nitrotyrosine-modified proteins was comparable in cerebral
artery lysate from T2D rats compared to control rats. This
is in contrast to studies in mouse aorta [59], rat aorta
[60], pig coronary artery [61], and rat epineurial arterioles
[62] that have shown increased nitrotyrosine expression
following high-fat feeding. Taken together, our data suggest
that, although antioxidant defence capacity is reduced, there
appears to be no vascular nitrosative stress in our experimen-
tal model of T2D.
4.8. Concluding Remarks. A number of caveats need to be
recognised here in terms of interpretation of our data. Firstly,
markers of oxidative and nitrosative stress were measured
within the cerebral vasculature while telomere length was
measured in DNA extracted from the peripheral vasculature.
Ideally, telomere length would have been measured within
cerebral arteries; however this was impossible given the
small size of rodent cerebral arteries. Secondly, the femoral
artery comprises a single layer of endothelial cells and a few
layers of smooth muscle cells. Therefore the smooth muscle
component largely outweighs the endothelial component. If
there are changes in endothelial cell telomere length in the
absence of smooth muscle cell changes, these would not be
detected.Thirdly, the qPCR assay as used in the present study
measures mean telomere length. There is evidence that a cell
may be triggered to enter senescence by a single critically
short telomere [63]. Therefore it remains a possibility that
there is telomere dysfunction within the T2D vasculature,
driven by a small number of critically short telomeres. Future
studies could address this possibility using high-throughput
quantitative fluorescence in situ hybridization [64].
In summary, we have shown for the first time that
leukocyte telomere length does not predict arterial telomere
length in T2D rats. Our findings highlight the importance of
measuring telomere dynamics in tissues other than circulat-
ing immune cells.
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